A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
…, L Chiecchio, NJ Dickens, MW Jenner… - Blood, The Journal …, 2010 - ashpublications.org
To obtain a comprehensive genomic profile of presenting multiple myeloma cases we
performed high-resolution single nucleotide polymorphism mapping array analysis in 114 …
performed high-resolution single nucleotide polymorphism mapping array analysis in 114 …
[HTML][HTML] Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised …
…, K Karunanithi, J Lindsay, MW Jenner… - The Lancet …, 2019 - thelancet.com
Background Patients with multiple myeloma treated with lenalidomide maintenance therapy
have improved progression-free survival, primarily following autologous stem-cell …
have improved progression-free survival, primarily following autologous stem-cell …
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a …
…, M Janakiram, I Jaiyesimi, M Jenner… - The Lancet …, 2019 - thelancet.com
Background As lenalidomide becomes increasingly established for upfront treatment of
multiple myeloma, patients refractory to this drug represent a population with an unmet need. …
multiple myeloma, patients refractory to this drug represent a population with an unmet need. …
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma
Multiple myeloma is characterized by genomic alterations frequently involving gains and
losses of chromosomes. Single nucleotide polymorphism (SNP)-based mapping arrays allow …
losses of chromosomes. Single nucleotide polymorphism (SNP)-based mapping arrays allow …
[HTML][HTML] Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients …
3. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1
blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress …
blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress …
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome
…, DC Johnson, JL Brito, A Zeisig, MW Jenner… - Clinical Cancer …, 2010 - AACR
Purpose: Myeloma is a clonal malignancy of plasma cells. Poor-prognosis risk is currently
identified by clinical and cytogenetic features. However, these indicators do not capture all …
identified by clinical and cytogenetic features. However, these indicators do not capture all …
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple …
We performed fluorescent in situ hybridization (FISH) for 16q23 abnormalities in 861 patients
with newly diagnosed multiple myeloma and identified deletion of 16q [del(16q)] in 19.5%. …
with newly diagnosed multiple myeloma and identified deletion of 16q [del(16q)] in 19.5%. …
Genome mining identifies cepacin as a plant-protective metabolite of the biopesticidal bacterium Burkholderia ambifaria
Beneficial microorganisms are widely used in agriculture for control of plant pathogens, but
a lack of efficacy and safety information has limited the exploitation of multiple promising …
a lack of efficacy and safety information has limited the exploitation of multiple promising …
[HTML][HTML] MMSET deregulation affects cell cycle progression and adhesion regulons in t (4; 14) myeloma plasma cells
Background The recurrent immunoglobulin translocation, t (4; 14)(p16; q32) occurs in 15%
of multiple myeloma patients and is associated with poor prognosis, through an unknown …
of multiple myeloma patients and is associated with poor prognosis, through an unknown …
Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications
Purpose: Deletions of chromosome 1 have been described in 7% to 40% of cases of
myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in …
myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in …